Anti-Complement component 5 Antibody, Non-Fucosylated (BioBet-089ZP) (CAT#: BioBet-089ZP) Datasheet

C5

Pexelizumab;h5G1.1-scFv;C5;complement component 5;complement C5;CPAMD4;anaphylatoxin C5a analog;C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4;FLJ17816;FLJ17822;MGC142298;

Extracellular region or secreted

Diseases associated with C5 include Complement Component 5 Deficiency and Eculizumab, Poor Response To.

Its related pathways are Immune response Lectin induced complement pathway and Signaling by GPCR.

1.C5 activated by C5 convertase initiates the spontaneous assembly of late complement components C5-c9 to form a membrane attack complex. C5b has a short-term binding site for C6. The C5b-C6 complex is the basis for the assembly of the cleavage complex. 2.C5 anaphylactic shock toxin is derived from the proteolytic degradation of complement C5 and is the mediator of the local inflammatory process. Binding to the receptor C5AR1 can cause a variety of reactions, including intracellular calcium release, smooth muscle contraction, increased vascular permeability, and histamine release from mast cells and basophils (PubMed:8182049). C5a is also a powerful chemokine, which stimulates the movement of polymorphonuclear leukocytes and guides them to migrate to the site of inflammation.

1.Glycosylation at Asn741, Asn911, Asn1115, and Asn1630 2.Modification sites at PhosphoSitePlus 3.Glycosylation from GlyConnect

Protein Based Therapies
Monoclonal antibody (mAb)

scFv

BioBet-089ZP

Humanized

Human

Recombinant humanized (from mouse) antibody expressed in CHO binding to human Complement component 5. Pexelizumab is a drug designed to reduce side effects of coronary artery bypass grafting and angioplasty, among other types of cardiac surgery. It is a single chain variable fragment of a monoclonal antibody targeted against component 5 of the complement system.

Cardiopulmonary bypass (CPB)

Cardiopulmonary bypass (CPB)